TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34694872
Drug: Telacebec (Q203)
Normalized name: Telacebec
DrugBank: Telacebec (DB17754)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telacebec (Q203) 10 to 800 mg (fed condition)
Study: 35401774
Drug: Osteopathic manipulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic manipulative treatment (OMT) + physiotherapy treatment (PT)
Study: 32213042
Drug: Antimicrobial therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial therapy for 3 days or less
Study: 32213042
Drug: Antimicrobial therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial therapy for 4 days or more
Study: 36067369
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (cholecalciferol) in men with baseline 25‐hydroxyvitamin D <20 ng/mL
Study: 34966900
Drug: Abatacept (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abatacept (125 mg subcutaneous every week)
Study: 35792520
Drug: Inotrope therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inotrope therapy
Study: 33452192
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel (chemotherapy)
Study: 32398341
Drug: 7 days
Normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 days antibiotic treatment
Study: 32398341
Drug: 14 days
Normalized name: ponesimod
DrugBank: Ponesimod (DB12016)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 14 days antibiotic treatment
Study: 32910135
Drug: Faricimab (dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faricimab (dosing every four months)
Study: 32910135
Drug: Faricimab (dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faricimab (dosing quarterly)
Study: 36493791
Drug: Bimekizumab 160
Normalized name: Bimekizumab 160 mg/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimekizumab 160 mg every 4 weeks (after switch from placebo at week 16)
Study: 36493791
Drug: Overall treatment-emergent
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment-emergent adverse events
Study: 35780106
Drug: SAYGo airway
Normalized name: inBreath airway transplant system
DrugBank: inBreath airway transplant system (DB18692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAYGo airway topical anesthesia and superior laryngeal nerve (SLN) block combined with transtracheal injection (TTI)
Study: 35780106
Drug: SAYGo airway
Normalized name: inBreath airway transplant system
DrugBank: inBreath airway transplant system (DB18692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAYGo airway topical anesthesia and SLN block combined with TTI
Study: 33939193
Drug: Systemic amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic amoxicillin (AMX) plus metronidazole (MTZ)
Study: 34322547
Drug: Single-inhaler triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-inhaler triple therapy (12.5 μg glycopyrronium, 12 μg formoterol, 250 μg fluticasone)
Study: 34322547
Drug: Open-triple therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-triple therapy (50 μg glycopyrronium co-administered with 12 μg formoterol and 250 μg fluticasone)
Study: 34357480
Drug: Oro-buccal administered
Normalized name: Oro Clense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oro-buccal administered cannabidiol-dominant anti-inflammatory formulation (MDCNB-02)
Study: 39506737
Drug: Craniosacral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Craniosacral therapy (CST)
Study: 616039576
Drug: Eye gel
Normalized name: EYE GEL
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eye gel (FC formulated as eye gel)
Study: 33766150
Drug: Sertraline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline plus olanzapine (n = 64)
Study: 33766150
Drug: Sertraline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline plus placebo (n = 62)
Study: 32812840
Drug: Stuttering treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stuttering treatment integrated with evidence-based parenting support (EBPS) for children with eADHD (eADHDintegrated)
Study: 32812840
Drug: Stuttering treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stuttering treatment only for children with eADHD (eADHDstandard)
Study: 32812840
Drug: Stuttering treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stuttering treatment only for children without eADHD (No-eADHDstandard)
Study: 32812840
Drug: Stuttering treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stuttering treatment integrated with EBPS for children with eADHD (eADHDintegrated)
Study: 35373603
Drug: Topical Tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical Tranexamic Acid (TA)
Study: 33370517
Drug: Nondamaging retinal
Normalized name: retinaldehyde
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nondamaging retinal laser therapy (NRT)
Study: 35982464
Drug: CC-99677
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-99677
Study: 32183608
Drug: Iodine-containing prenatal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodine-containing prenatal multiple micronutrient (MMN) supplement (300 μg of iodine)
Study: 32183608
Drug: Iron and
Normalized name: beef,iron and wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron and folic acid (FeFol) supplement
Study: 35191982
Drug: Ticagrelor in
Normalized name: Product containing ticagrelor in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor in preadmission aspirin and/or clopidogrel group
Study: 35191982
Drug: Prasugrel in
Normalized name: Product containing prasugrel in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel in preadmission aspirin and/or clopidogrel group
Study: 35191982
Drug: Ticagrelor in
Normalized name: Product containing ticagrelor in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor in no preadmission aspirin or clopidogrel group
Study: 35191982
Drug: Prasugrel in
Normalized name: Product containing prasugrel in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel in no preadmission aspirin or clopidogrel group
Study: 33370510
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg intravenous ketorolac
Study: 33370510
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg intravenous ketorolac
Study: 33370510
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg intravenous ketorolac
Study: 33370510
Drug: Rescue analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue analgesic (0.1 mg/kg intravenous morphine sulfate)
Study: 33430891
Drug: Methylprednisolone (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (120 mg IV once daily on days 1, 2, and 3) plus standard of care
Study: 33430891
Drug: Placebo (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.9% saline IV once daily on days 1, 2, and 3) plus standard of care
Study: 34967844
Drug: GnRHa (3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRHa (3.6 mg goserelin or 3.75 mg leuprorelin injected subcutaneously once every 28 days)
Study: 34967844
Drug: Control (chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (chemotherapy without GnRHa)
Study: 33588478
Drug: Xylazine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylazine (0.1 mg/kg)
Study: 33588478
Drug: Detomidine (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detomidine (0.03 mg/kg)
Study: 32480409
Drug: Goserelin acetate
Normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Goserelin acetate plus 0 grams of testosterone gel (placebo)
Study: 32480409
Drug: Goserelin acetate
Normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Goserelin acetate plus 1.25 grams of testosterone gel
Study: 32480409
Drug: Goserelin acetate
Normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Goserelin acetate plus 2.5 grams of testosterone gel
Study: 32480409
Drug: Goserelin acetate
Normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Goserelin acetate plus 5 grams of testosterone gel
Study: 32480409
Drug: Goserelin acetate
Normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Goserelin acetate plus 10 grams of testosterone gel
Study: 38485313
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL 0.5% bupivacaine
Study: 35524405
Drug: Eptinezumab (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eptinezumab (100 mg and 300 mg doses)
Study: 33187890
Drug: Extended-release tolterodine
Normalized name: tolterodine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release tolterodine
Study: 33487155
Drug: Rivaroxaban 15
Normalized name: rivaroxaban 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 15 mg/day (n=73)
Study: 33487155
Drug: Warfarin (n=36)
Normalized name: (-)-Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Warfarin (n=36)
Study: 33084584
Drug: Baseline daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline daily steps
Study: 36654481
Drug: Concentrated pomegranate
Normalized name: Pomegranate
DrugBank: Pomegranate (DB14317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentrated pomegranate juice (PJ) 45 ml/day
Study: 33472675
Drug: C1 esterase/kallikrein
Approvals — FDA: no, EMA: no, PMDA: no
Description: C1 esterase/kallikrein inhibitor 20 U/kg intravenously on day 1 and day 4 plus standard care
Study: 33472675
Drug: Icatibant 30
Normalized name: icatibant 30 MG in 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icatibant 30 mg subcutaneously, three doses/day for 4 days plus standard care
Study: 36156313
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard chemo-mechanical treatment)
Study: 33357677
Drug: Daily feed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily feed intake (DFI)
Study: 34808036
Drug: 3.7 g
Normalized name: Toxi-Sorb 3.7 GM Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.7 g day-1 n-3 fatty acids (fish oil)
Study: 35396307
Drug: Low-dose naltrexone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose naltrexone (LDN) 4.5 mg once daily for 12 weeks
Study: 34120223
Drug: T-DM1 3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-DM1 3.6 mg/kg IV every 3 weeks × 17
Study: 34120223
Drug: Paclitaxel (T)
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel (T) 80 mg/m2 with trastuzumab (H) IV qw × 12 (4 mg/kg load → 2 mg/kg), followed by H (6 mg/kg IV q3w × 13)
Study: 32538009
Drug: Oral analgesics
Normalized name: ANALGESIC CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral analgesics (bucinnazine hydrochloride and oxycodone hydrochloride)
Study: 33908343
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavioral therapy for insomnia (ICBT-I)
Study: 34490711
Drug: Rhythmic eye
Normalized name: ALUMINUM ZIRCONIUM TRICHLOROHYDREX GLY 180 mg in 1 g TOPICAL STICK [ZUSKA RHYTHM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhythmic eye movements during virtual reality exposure therapy (VRET)
Study: 32294883
Drug: Apple Polyphenol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apple Polyphenol (AP) 300 mg/day
Study: 32294883
Drug: Apple Polyphenol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apple Polyphenol (AP) 600 mg/day
Study: 35581106
Drug: Cardamom inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardamom inhalation therapy
Study: 34288956
Drug: Substance use
Normalized name: reSET Substance Use Disorder Therapy Software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substance use (smoking, drug use, alcohol consumption)
Study: 33580692
Drug: Lactononadecapeptide (LNDP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactononadecapeptide (LNDP) tablets
Study: 39188412
Drug: Traction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traction therapy (TT)
Study: 33390422
Drug: Post-meal fast-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-meal fast-acting insulin aspart
Study: 32926418
Drug: 450 mg
Normalized name: aspirin 450 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450 mg Valganciclovir (VGCV) daily
Study: 32926418
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg Valganciclovir (VGCV) daily
Study: 32926418
Drug: Sampling strategies
Normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sampling strategies of plasma concentrations at 0 and 2 hours and 0, 2, and 4 hours after VGCV administration
Study: 34454788
Drug: Rotavirus vaccine
Normalized name: rotavirus vaccine
DrugBank: Rotavirus vaccine (DB10276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotavirus vaccine (RV) with routine EPI vaccines
Study: 33207993
Drug: Partial Enteral
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partial Enteral Nutrition (PEN) - casein-based formula for 12 months providing 25% of estimated daily energy requirements
Study: 33196153
Drug: Subcutaneous evinacumab
Normalized name: Evinacumab
DrugBank: Evinacumab (DB15354)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subcutaneous evinacumab 450 mg weekly
Study: 33196153
Drug: Subcutaneous evinacumab
Normalized name: Evinacumab
DrugBank: Evinacumab (DB15354)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subcutaneous evinacumab 300 mg weekly
Study: 33196153
Drug: Subcutaneous evinacumab
Normalized name: Evinacumab
DrugBank: Evinacumab (DB15354)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subcutaneous evinacumab 300 mg every 2 weeks
Study: 33196153
Drug: Intravenous evinacumab
Normalized name: Evinacumab
DrugBank: Evinacumab (DB15354)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous evinacumab 15 mg/kg every 4 weeks
Study: 33196153
Drug: Intravenous evinacumab
Normalized name: Evinacumab
DrugBank: Evinacumab (DB15354)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous evinacumab 5 mg/kg every 4 weeks
Study: 32883723
Drug: Online cognitive-behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online cognitive-behavioural therapy (CBT)
Study: 34981621
Drug: Biocon's Insulin‐R
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biocon's Insulin‐R
Study: 35190972
Drug: QLHER2 (test)
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: QLHER2 (test) at single doses escalating from 0.2 to 6 mg/kg
Study: 35190972
Drug: Herceptin (reference)
Normalized name: Herceptin
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Herceptin (reference) at 4 mg/kg
Study: 33137340
Drug: EOS789 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: EOS789 50 mg
Study: 33137340
Drug: EOS789 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: EOS789 100 mg
Study: 33137340
Drug: EOS789 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: EOS789 100 mg plus 1600 mg sevelamer
Study: 35565859
Drug: Amorphous Calcium
Normalized name: Casein Phosphopeptide-Amorphous Calcium Phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amorphous Calcium Carbonate (ACC) supplementation (2000 mg per day)
Study: 32835498
Drug: 47 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 47 g/kg sunflower meal (SFM)
Study: 32835498
Drug: 97 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 97 g/kg sunflower meal (SFM)
Study: 32835498
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet (corn and soybean meal, 30 g/kg crude fibre)
Study: 35426485
Drug: Newly developed
Normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Newly developed biological therapies
Study: 35426485
Drug: Traditional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional therapy with first- and second-line drugs
Study: 32758672
Drug: Role-playing twice
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Role-playing twice
Study: 33184931
Drug: Atrasentan 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrasentan 0.75 mg for six weeks
Study: 34127610
Drug: Flywheel training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flywheel training (twice weekly squat and calf raise exercises for 6 weeks)
Study: 36480811
Drug: zanubrutinib (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: zanubrutinib (80 mg BID) with moderate CYP3A inhibitors fluconazole and diltiazem
Study: 36480811
Drug: zanubrutinib (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: zanubrutinib (80 mg QD) with strong CYP3A inhibitor voriconazole
Study: 36480811
Drug: zanubrutinib (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: zanubrutinib (320 mg QD)
Study: 33661781
Drug: Oral carbohydrate
Normalized name: omega-3 carboxylic acids Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral carbohydrate (group OC)
Study: 33661781
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo (group OP)
Study: 35078853
Drug: 3-weekly durvalumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-weekly durvalumab 1500 mg plus 3-weekly doublet chemotherapy (cisplatin 75 mg/m2 or carboplatin, AUC 5 and pemetrexed 500 mg/m2) for 4-6 cycles, followed by 4-weekly durvalumab 1500 mg until disease progression, unacceptable toxicity or patient withdrawal
Study: 35078853
Drug: Doublet chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doublet chemotherapy alone for 4-6 cycles, followed by observation
Study: 33238010
Drug: Digital rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital rehabilitation program (application) along with traditional physical therapy (PT)
Study: 33238010
Drug: Traditional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional physical therapy (PT)
Study: 39698346
Drug: SGLT2 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SGLT2 inhibitors (SGLT2i)
Study: 33271428
Drug: GLP1 receptor
Normalized name: XTEN-GLP1
DrugBank: Vurolenatide (DB18440)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP1 receptor agonists (GLP1RA)
Study: 35149638
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy support (counseling, relaxation, mindfulness-based exercises)
Study: 33810808
Drug: 500 ml
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml pomegranate juice and standard of care hospital treatment for COVID-19
Study: 33810808
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo containing 500 ml of red water and standard of care hospital treatment for COVID-19
Study: 34527079
Drug: Oral nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutritional supplements (ONSs) with a high‐protein–high‐calorie mixture containing immunonutrients (Impact)
Study: 32293119
Drug: Intraarticular injection
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraarticular injection of trans-capsaicin
Study: 36364934
Drug: HMB +
Normalized name: Hydroxymethylbutyrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMB + D (3 g Calcium HMB + 2000 IU D per day)
Study: 33982872
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 5 mg tablet daily for 12 weeks
Study: 33982872
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 5 mg tablet
Study: 32860406
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of bone marrow-derived mononuclear cells (BM-MNCs) 2-8 days after PPCI
Study: 32860406
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of bone marrow-derived mononuclear cells (BM-MNCs)
Study: 35198913
Drug: Reactive focal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reactive focal mass drug administration (rfMDA)
Study: 33916192
Drug: Probiotic preparation
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic preparation comprising Lactobacillus rhamnosus ŁOCK 0900, Lactobacillus rhamnosus ŁOCK 0908, and Lactobacillus casei ŁOCK 0918 at a daily dose of 10^9 bacteria for three months.
Study: 32173916
Drug: guselkumab 100
Normalized name: guselkumab 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: guselkumab 100 or 200 mg at weeks 0, 4, 12 and every 8 weeks
Study: 32173916
Drug: guselkumab 100
Normalized name: guselkumab 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: guselkumab 100 or 200 mg
Study: 35675561
Drug: 2 Mini
Normalized name: CLN2 RDNA CONSTRUCT DISRUPTING EXON 6 OF CLN2 GENE IN YUCATAN MINIATURE SWINE 1 [arb'U] in 1 [arb'U] NOT APPLICABLE NOT APPLICABLE [ExeGen CLN2 miniswine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 Mini Dental Implants (2MDI)
Study: 35675561
Drug: 4 Mini
Normalized name: wheat germ oil 14 minim ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 Mini Dental Implants (4MDI)
Study: 35675561
Drug: 2 Conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 Conventional Dental Implants (2CDI)
Study: 35927547
Drug: Untailored information
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Untailored information derived from the Vaccine Information Sheet (VIS)
Study: 33400099
Drug: Enoxaparin 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 0.5 mg/kg daily (weight-based dosing)